GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Simris Alg AB (OSTO:SIMRIS B) » Definitions » Total Liabilities

Simris Alg AB (OSTO:SIMRIS B) Total Liabilities : kr147.72 Mil (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Simris Alg AB Total Liabilities?

Simris Alg AB's Total Liabilities for the quarter that ended in Mar. 2025 was kr147.72 Mil.

Simris Alg AB's quarterly Total Liabilities declined from Sep. 2024 (kr160.56 Mil) to Dec. 2024 (kr151.42 Mil) and declined from Dec. 2024 (kr151.42 Mil) to Mar. 2025 (kr147.72 Mil).

Simris Alg AB's annual Total Liabilities declined from Dec. 2022 (kr162.68 Mil) to Dec. 2023 (kr148.94 Mil) but then increased from Dec. 2023 (kr148.94 Mil) to Dec. 2024 (kr151.42 Mil).


Simris Alg AB Total Liabilities Historical Data

The historical data trend for Simris Alg AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simris Alg AB Total Liabilities Chart

Simris Alg AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.64 10.98 162.68 148.94 151.42

Simris Alg AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 153.70 158.23 160.56 151.42 147.72

Simris Alg AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Simris Alg AB's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=15.969+(1.366+134.081
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=151.42

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=157.057-5.641
=151.42

Simris Alg AB's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=20.573+(0+127.148
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=147.72

Total Liabilities=Total Assets (Q: Mar. 2025 )-Total Equity (Q: Mar. 2025 )
=146.65--1.071
=147.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Simris Alg AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Simris Alg AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Simris Alg AB Business Description

Traded in Other Exchanges
Address
Herrestadsvagen 24A, Hammenhog, SWE, 276 50
Simris Alg AB is a biotechnology company, engaged in research, development and production of bioactive substances from microalgae, for nutraceutical, cosmeceutical and pharmaceutical applications. The company's technology provides access to bioactive substances with novel functions, while replacing unsustainable raw materials from endangered marine species and ecosystems. Its first commercialised range is a series of omega-3 health supplements marketed under the company's own brand.

Simris Alg AB Headlines

No Headlines